Quadruple or triple therapy to eradicate H pylori

The Lancet

Volumn 377, Issue 9769, 2011, Pages 877-878

  Lee, Byoung Hwan ^a   Kim, Nayoung ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; DRUG EFFICACY; HELICOBACTER INFECTION; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 79952485189     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60168-2     Document Type: Note

References (11)

1. Malfertheiner P, Bazzoli F, Delchier J-C, et al, for the Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; published online Feb 22. DOI:10.1016/S0140-6736(11)60020-2.
2. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65-73.
3. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-67. (Pubitemid 36348526)
4. Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38-45.
5. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006; 28: 6-13.
6. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.
7. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010; 8: 36-41.
8. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009; 14: 109-18.
9. Sánchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Titó L, Castro M. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008; 103: 2220-23.
10. Kwon JH, Lee DH, Song BJ, et al. Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study. Helicobacter 2010; 15: 148-53.
11. Choi WH, Park DI, Oh SJ, et al. Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea. Korean J Gastroenterol 2008; 51: 280-84 (in Korean).